Today's episode is with the CEO and founder of Vistim Labs, James Hamet. In addition to building mind-controlled wheelchairs and ice sculpting, Mr. Hamet focuses on tracking cognitive decline in individuals with neurodegenerative diseases, accelerating diagnosis while allowing for effective disease management in the future. This is done with a technology his company created, which we explore further in this episode.
Currently, treatment for Alzheimer's, Parkinson's, and other neurodegenerative conditions is based on preventing symptoms that arise as the disease progresses. However, Mr. Hamet shares why this approach is inefficient and why early detection of neurodegenerative conditions can significantly improve patients' course of treatment and quality of life. In this episode, we also discuss how visuospatial deficits impact those with Alzheimer's and how Vistim Labs utilizes these to track cognitive decline. Mr. Hamet additionally shares Vistim Labs' goals for the future, as well as his ambitions and past setbacks. With partners from all over the globe, Vistim Labs seeks to expand its clinical utility to other disease categories, like Traumatic Brain Injury and Schizophrenia!
Make sure to subscribe to the Neurological Disorder Podcast on Spotify, Apple Podcasts, or wherever you listen to your podcasts!
Follow me on Instagram- @neurologicaldisorderpodcast
Email me at- neurologicaldisorderpodcast@gmail.com
Mentioned links:
Today's episode is with the CEO and founder of Vistim Labs, James Hamet. In addition to building mind-controlled wheelchairs and ice sculpting, Mr. Hamet focuses on tracking cognitive decline in individuals with neurodegenerative diseases, accelerating diagnosis while allowing for effective disease management in the future. This is done with a technology his company created, which we explore further in this episode.
Currently, treatment for Alzheimer's, Parkinson's, and other neurodegenerative conditions is based on preventing symptoms that arise as the disease progresses. However, Mr. Hamet shares why this approach is inefficient and why early detection of neurodegenerative conditions can significantly improve patients' course of treatment and quality of life. In this episode, we also discuss how visuospatial deficits impact those with Alzheimer's and how Vistim Labs utilizes these to track cognitive decline. Mr. Hamet additionally shares Vistim Labs' goals for the future, as well as his ambitions and past setbacks. With partners from all over the globe, Vistim Labs seeks to expand its clinical utility to other disease categories, like Traumatic Brain Injury and Schizophrenia!
Make sure to subscribe to the Neurological Disorder Podcast on Spotify, Apple Podcasts, or wherever you listen to your podcasts!
Follow me on Instagram- @neurologicaldisorderpodcast
Email me at- neurologicaldisorderpodcast@gmail.com
Mentioned links: